Sanofi (SNY )

Currency in USD Disclaimer
$54.57 -$0.35 (-0.64%)
Closed 10/15/2024
$53.84
$54.93
$42.63
$58.97

Company brief: SANOFI (SNY )


Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

SNY Corporation News

France considering stake in Sanofi's Opella, minister says

October 15, 2024 at 11:47 am ET

reuters.com -- France is considering taking a stake in Sanofi's Opella arm, said finance minister Antoine Armand, to allay concerns that the French drugmaker's plans to sell a 50% stake in Opella to a U.S. private e...

Should Value Investors Buy Sanofi (SNY) Stock?

October 14, 2024 at 10:49 am ET

zacks.com -- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

French government seeking job guarantees from Sanofi over Doliprane production sites

October 14, 2024 at 7:01 am ET

reuters.com -- The French government is seeking job guarantees from drugmaker Sanofi regarding its Doliprane production sites in the event of a sale of its consumer health branch, Economy Minister Antoine Armand sai...

Sanofi in talks to sell consumer healthcare business that makes Dulcolax

October 11, 2024 at 4:32 am ET

marketwatch.com -- Sanofi on Friday said it's in talks with the private equity firm CD&R to sell just over half of its consumer healthcare business, in a deal that could yield billions of dollars for the French drugmake...

Sanofi in talks to sell 50% stake in consumer health business to CD&R

October 11, 2024 at 2:43 am ET

reuters.com -- Sanofi has entered into discussions with U.S. private equity firm Clayton Dubilier & Rice to sell a controlling 50% stake in its consumer health business Opella, the French pharmaceutical giant said o...

Press Release: Sanofi in discussions to sell a controlling stake in Opella

October 11, 2024 at 2:30 am ET

globenewswire.com -- Sanofi in discussions to sell a controlling stake in Opella Paris, October 11, 2024 . Sanofi today announces that the company has entered into negotiations with CD&R for the potential sale of a 50% co...

CD&R nears deal to buy Sanofi's consumer unit for $16 bln, Bloomberg News reports

October 10, 2024 at 5:09 pm ET

reuters.com -- Private equity firm Clayton Dubilier & Rice (CD&R) is nearing a deal to acquire Sanofi's consumer health unit for about 15 billion euros ($16.4 billion), Bloomberg News reported on Thursday....

Denali-Sanofi scraps mid-stage study for multiple sclerosis drug

October 10, 2024 at 4:19 pm ET

reuters.com -- Drug developer Denali Therapeutics said on Thursday its partner Sanofi has discontinued a mid-stage study testing their experimental drug to treat multiple sclerosis as it failed to meet the main and ...

Income Statement